Combination therapy with enfortumab vedotin, a Nectin-4-targeted antibody-drug conjugate, and pembrolizumab, an anti-PD1 antibody, recently supplanted platinum-based chemotherapy as standard first-line systemic therapy for patients with muscle-invasive or metastatic urothelial cancer. A composite biomarker integrating...
James A. Rodrigues, H. Al-Ahmadie, D. Aggen et al.· Clinical Cancer Research· 0 citations
Wide variation in outcomes is observed for patients with hormone-receptor-positive metastatic breast cancer (MBC) receiving first-line CDK4/6 inhibitors plus endocrine therapy (CDK4/6i+ET). Although front-line escalation strategies are beginning to enter clinical practice, assigning patients to intensified or de-intens...
L. Boscolo Bielo, F. Sánchez-Vega, Subhiksha Nandakumar et al.· Research Square· 0 citations
The data suggest that despite the heterogeneity in CRC, genomic evolution increases the impact of recurrent alterations, and integrating information about tumor primary location and genomics can be used to predict organ-specific metastasis risk.
Paolo Manca, H. Walch, Jierui Xu et al.· Cancer Cell· 1 citation
T-DM1 demonstrated heterogenous efficacy among HER2-amplified tumor types, with promising response and outcomes among patients with salivary gland cancer.
J. Ross, W. Wong, Lauren Schoech et al.· Clinical Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
